A Study of CIN-107 in Adults With Primary Aldosteronism
Status:
Recruiting
Trial end date:
2022-03-28
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, placebo-controlled, multicenter, parallel-group, dose-ranging
study in patients with PA to evaluate the efficacy and safety of up to 3 doses of CIN-107 as
compared to placebo after 4 weeks of treatment.